In ccRCC, where the survival rate is no >11 % in aggressive or metastasized tumors, it has been demonstrated that SETD2 mutants are sensitive in vitro and in vivo to DNA hypomethylating agent 5-aza-2′-deoxycytidine (DAC) treatment. Here, SETD2 is linked to nonpapillary renal cell carcinoma.